11 hasil untuk "Gitzinger, Marc"

Controlling transgene expression in subcutaneous implants using a skin lotion containing the apple metabolite phloretin

Gitzinger, Marc; Kemmer, Christian; El-Baba, Marie Daoud dkk.

Proc Natl Acad Sci U S A · 2009 · Inggris · PubMed Central

Adjustable control of therapeutic transgenes in engineered cell implants after transdermal and topical delivery of nontoxic trigger molecules would increase convenience, patient compliance, and elimination of hepatic first-pass effect in future therapies. Pseudomonas putida DOT-T1E has evolved the…

The food additive vanillic acid controls transgene expression in mammalian cells and mice

Gitzinger, Marc; Kemmer, Christian; Fluri, David A. dkk.

Nucleic Acids Res · 2011 · Inggris · PubMed Central

Trigger-inducible transcription-control devices that reversibly fine-tune transgene expression in response to molecular cues have significantly advanced the rational reprogramming of mammalian cells. When designed for use in future gene- and cell-based therapies the trigger molecules have to be…

The Role of OmpR in Bile Tolerance and Pathogenesis of Adherent-Invasive Escherichia coli

Lucchini, Valentina; Sivignon, Adeline; Pieren, Michel dkk.

Front Microbiol · 2021 · Inggris · PubMed Central

Gut microbiota dysbiosis toward adherent-invasive Escherichia coli (AIEC) plays an important role in Crohn’s disease (CD). The OmpR transcriptional regulator is required for the AIEC LF82 prototype strain to adhere and invade intestinal epithelial cells. In this study, we explored the role of OmpR…

Phenylethyl Butyrate Enhances the Potency of Second-Line Drugs against Clinical Isolates of Mycobacterium tuberculosis

Grau, Thomas; Selchow, Petra; Tigges, Marcel dkk.

Antimicrob Agents Chemother · 2012 · Inggris · PubMed Central

Ethionamide (ETH) is a second-line drug for the treatment of tuberculosis. As a prodrug, ETH has to be activated by EthA. ethA is controlled by its repressor EthR. 2-Phenylethyl-butyrate (2-PEB) inhibits EthR binding, enhances expression of EthA, and thereby enhances the growth-inhibitory effects…

A synthetic mammalian gene circuit reveals antituberculosis compounds

Weber, Wilfried; Schoenmakers, Ronald; Keller, Bettina dkk.

Proc Natl Acad Sci U S A · 2008 · Inggris · PubMed Central

Synthetic biology provides insight into natural gene-network dynamics and enables assembly of engineered transcription circuitries for production of difficult-to-access therapeutic molecules. In Mycobacterium tuberculosis EthR binds to a specific operator (O(ethR)) thereby repressing ethA and…

Dissecting Colistin Resistance Mechanisms in Extensively Drug-Resistant Acinetobacter baumannii Clinical Isolates

Trebosc, Vincent; Gartenmann, Sarah; Tötzl, Marcus dkk.

mBio · 2019 · Inggris · PubMed Central

Nosocomial infections with Acinetobacter baumannii are a global problem in intensive care units with high mortality rates. Increasing resistance to first- and second-line antibiotics has forced the use of colistin as last-resort treatment, and increasing development of colistin resistance in A…

In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms

Trebosc, Vincent; Schellhorn, Birgit; Schill, Julian dkk.

J Antimicrob Chemother · 2020 · Inggris · PubMed Central

BACKGROUND: Rifabutin, an oral drug approved to treat Mycobacterium avium infections, demonstrated potent activity against Acinetobacter baumannii in nutrient-limited medium enabled by rifabutin cellular uptake through the siderophore receptor FhuE. OBJECTIVES: To determine rifabutin in vitro…

A Novel Genome-Editing Platform for Drug-Resistant Acinetobacter baumannii Reveals an AdeR-Unrelated Tigecycline Resistance Mechanism

Trebosc, Vincent; Gartenmann, Sarah; Royet, Kevin dkk.

Antimicrob Agents Chemother · 2016 · Inggris · PubMed Central

Infections with the Gram-negative coccobacillus Acinetobacter baumannii are a major threat in hospital settings. The progressing emergence of multidrug-resistant clinical strains significantly reduces the treatment options for clinicians to fight A. baumannii infections. The current lack of robust…

Revival of Ethionamide by Alpibectir (BVL-GSK098)

Pieren, Michel; Dale, Glenn E.; Gitzinger, Marc dkk.

N Engl J Med · 2026 · Inggris · PubMed Central

Targeting virulence regulation to disarm Acinetobacter baumannii pathogenesis

Trebosc, Vincent; Lucchini, Valentina; Narwal, Mohit dkk.

Virulence · 2022 · Inggris · PubMed Central

The development of anti-virulence drug therapy against Acinetobacter baumannii infections would provide an alternative to traditional antibacterial therapy that are increasingly failing. Here, we demonstrate that the OmpR transcriptional regulator plays a pivotal role in the pathogenesis of diverse…

First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug

Pieren, Michel; Abáigar Gutiérrez-Solana, Ana; Antonijoan Arbós, Rosa María dkk.

J Antimicrob Chemother · 2024 · Inggris · PubMed Central

BACKGROUND: The clinical candidate alpibectir augments the activity of, and overcomes resistance to, the anti-TB drug ethionamide in vitro and in vivo. OBJECTIVES: A Phase 1, double-blind, randomized, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics (PK) and food…